

Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia

Dhananjay Yellajoshyula, PhD,^{1*} Samuel S. Pappas, PhD,^{2,3} and William T. Dauer, MD^{2,3,4*}

¹Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA

²Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA

³Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

⁴Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas, USA

ABSTRACT: The quest to elucidate nervous system function and dysfunction in disease has focused largely on neurons and neural circuits. However, fundamental aspects of nervous system development, function, and plasticity are regulated by nonneuronal elements, including glial cells and the extracellular matrix (ECM). The rapid rise of genomics and neuroimaging techniques in recent decades has highlighted neuronal–glial interactions and ECM as a key component of nervous system development, plasticity, and function. Abnormalities of neuronal–

glial interactions have been understudied but are increasingly recognized to play a key role in many neurodevelopmental disorders. In this report, we consider the role of myelination and the ECM in the development and function of central nervous system motor circuits and the neurodevelopmental disease dystonia. © 2022 International Parkinson and Movement Disorder Society

Key Words: dystonia; white matter; oligodendrocyte; ECM; plasticity

Dystonia manifests as prolonged involuntary twisting movements that occur either in isolation or in combination with other neurological symptoms.^{1,2} The pathophysiology of dystonia is complex with cellular and circuit dysfunctions from multiple regions implicated thus far.³ Functional and molecular deficiencies observed in animal models and in multiple inherited forms of dystonia include cholinergic dysfunction,^{4–10} impaired inhibition,^{11–15} abnormal connectivity,^{16–21} and deficits in plasticity.^{22–24} These core features highlight the varied mechanisms contributing to dystonia pathophysiology, which lead to remarkably similar motor deficits. Many of these phenotypes emerge during central nervous system (CNS) maturation, which is supported by recent studies

using animal models manipulating TorsinA (*Tor1A* or *DYT1*) expression, demonstrating its importance during a “critical period” of neurodevelopment.^{22,25–27} These findings and the recent identification of several monogenic variants with high diagnostic value in early-onset dystonias^{28–30} offer strong support to the premise that dysregulation of neurodevelopmental mechanisms is a key feature of dystonia pathophysiology.

Advances in sequencing technologies have expanded our understanding of the genes associated with dystonia.^{2,31,32} Genetic mutations causing isolated (*TOR1A*, *THAP1*, *GNAL*, *ANO3*, *PRKRA*, *KMT2B*, *GCH1*, and *HPCA*) and combined dystonia (*ATP1A3*, *SGCE*, *TAF1*, *SLC2A1/GLUT1*, *PNKD*, *PRRT2*, *VPS16*, *VPS41*, and *KCTD17*) are all ubiquitously expressed in the CNS (Fig. 1; single-cell portal; BROAD Institute: https://singlecell.broadinstitute.org/single_cell). Most dystonia-associated genes are expressed in both neuronal and glial cells (Fig. 1), with only *ATP1A3* expression exhibiting neuronal restricted expression (confirmed in single-cell portal, by the BROAD Institute, and at <https://www.brainrnaseq.org>). These observations are consistent with the possibility that dystonia etiology is not limited to mechanisms originating from neuronal cells. In this report, we examine emerging

*Correspondence to: Dr. W.T. Dauer, Simmons Biomedical Research Building, NB5.604, 6000 Harry Hines Blvd. Dallas, TX 75390, USA; E-mail: william.dauer@utsouthwestern.edu; or Dr. D. Yellajoshyula, Department of Neurology, University of Michigan, 5027, BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA; E-mail: dyellaj@med.umich.edu

Relevant conflicts of interest/financial disclosures: None.

Received: 16 September 2021; Revised: 17 November 2021; Accepted: 3 December 2021

Published online 6 January 2022 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28892




FIG. 1. Central nervous system cell-type-specific expression of dystonia genes. Dot plot showing the expression pattern of inherited dystonia genes (rows) derived from single-nucleus RNA sequencing of mouse cortex (single-cell portal, BROAD Institute).³³ The relative expression of genes in various cell types (columns) is scaled (0–1 = blue to red) relative to each gene's expression across all cells. The size of the dot represents the relative expression in the given cell type. OPC, oligodendrocyte progenitor cell.

evidence implicating abnormalities of the extracellular matrix, myelination, and axon–glia interactions in motor function and dystonia pathogenesis.

White Matter and Oligodendrogenesis in Motor Learning and Plasticity

Generation of white matter (WM) in the brain is a gradual postnatal process as observed in humans and

rodents whereby oligodendrocyte cells (referred to as OLs) wrap axons with a myelin sheath that supports rapid neurotransmission.³⁴ These myelinating glial cells differentiate from oligodendrocyte progenitor cells (OPCs). Peak myelination in the developing brain occurs concomitant with peak synaptogenesis, with the bulk of it occurring in the first 2 years in humans and the first 3 weeks in rodents.^{35–37} However, myelination continues through puberty in both animals and humans,³⁷ including changes in myelinated WM volumes in frontal brain regions that can be detected in humans up to 40 years of age.^{38,39} Thus, critical periods during the emergence of sensory and motor function coincide with the differentiation of OPCs into myelinating OLs.

Studies in mice have established that motor learning promotes key aspects of oligodendrogenesis, including increased OPC proliferation, generation of mature myelin-producing OLs,^{40,41} and myelin sheath remodeling.⁴² Increased oligodendrogenesis from motor learning is a critical aspect of “adaptive myelination,” whereby neural activity promotes the generation of myelinating OLs.^{43,44} In an elegant approach, Gibson et al.⁴⁵ demonstrated that optogenetic stimulation of layer V projection neurons in the premotor cortex promotes oligodendrogenesis, increases myelin thickness, and alters motor function.

Although changes in myelination in animal models can be quantitatively assessed through many techniques and reagents postmortem, in humans and live animal studies WM tracts are commonly assessed using the magnetic resonance imaging technique diffusion tensor imaging (DTI). This technique measures water diffusion as a proxy for the integrity and organization of axonal tracts.^{46,47} Fraction anisotropy (FA), a measure of the orientation dependence of water diffusion, is a DTI parameter that is commonly used to assess tract integrity.^{46,47} FA values are higher in WM tracts compared with gray matter due to the highly organized axonal bundles that restrict water diffusion along defined paths.^{47,48} Although higher FA values positively correlate with axonal myelination⁴⁸ and low FA values are observed in demyelinating disorders,⁴⁶ WM integrity is also dependent on axon density, caliber, and the presence of other glial cells. Thus FA is a biomarker of microstructural architecture⁴⁷ but is not exclusive to changes in myelination.

Several DTI studies indicate that motor skill learning causes WM structural changes. For example, corticospinal tract FA values increase with extensive piano practicing,⁴⁹ while juggling training increases FA in the intraparietal sulcus.⁵⁰ Interestingly, the whole-body movement paradigm Quadrato Motor Training induces FA increases across multiple WM regions, including the corticospinal tract, anterior thalamic radiations, and uncinate fasciculi.⁵¹ Motor learning also

induces WM changes in laboratory models. Learning a highly skilled reaching task increased FA in the WM of the sensorimotor cortex contralateral to the trained limb compared with untrained control rats, and ex vivo myelin staining density correlated with learning rate.⁵²

A critical question is whether the activity-induced myelination and oligodendrogenesis are necessary for motor learning and skill. This question was addressed directly by disrupting the generation of new OLs in animals learning the skill of running on a wheel with unequally placed rungs.^{40,41} These investigators conditionally deleted from OPCs *Myrf*, a factor critical for differentiation of OPC to OL. This perturbation impaired the generation of myelinating OLs and caused deficits in the wheel task, particularly in the early stages of motor learning.^{40,41} Similar motor learning deficits were observed in studies using cuprizone-induced demyelination in mice performing skilled reaching, where demyelination is followed by incomplete OL replacement and motor learning defects.⁴²

Genetic Links Between WM, Oligodendrocyte Dysfunction, and Dystonia

Parallel to the work linking WM and motor learning are clinical and laboratory studies implicating alterations of WM in the pathophysiology of dystonia. Changes in WM microstructure have been reported in patients with 12 different forms of inherited dystonia, either in isolation or in combination with other neurological symptoms (Table 1). Eight of the mutated genes implicated in primary (Table 1; *THAP1*, *YY1*, *TUBB4A*) and secondary dystonia (Table 1; *SLC2A1/GLUT1*, *BAP31*, *FA2H*, *SLC16A2/MCT8*, and *POLR3*) have an established role in myelination. Several additional studies have reported microstructural WM changes in idiopathic dystonias.⁸⁵ For example, significant changes in FA values have been reported in subjects with cervical dystonia in the putamen, corpus callosum,⁸⁶ and internal globus pallidus.^{87,88} Similar findings have been reported in patients with “writer’s cramp” (a form of task-specific dystonia) and spasmodic dysphonia.⁴⁶⁻⁴⁸

Studies of *THAP1* function are the first direct demonstration of a primary dystonia gene functioning in the oligodendrocyte lineage.^{54,56} *DYT-THAP1* (*DYT6* dystonia) is caused by loss-of-function mutations in *THAP1*,⁸⁹ a transcription factor with an atypical zinc-dependent DNA-binding domain.^{90,91} More than 100 mutations have been reported in the protein-coding region of this gene.⁹² We reported that, despite its ubiquitous expression (Fig. 1),⁵⁴ *THAP1*-regulated pathways are highly enriched within the OL lineage.⁵⁴ Mice conditionally deficient for *Thap1* in the entire CNS

(using Nestin-cre) or conditionally deficient for *Thap1* in the OL lineage (using Olig2-Cre) exhibit severe myelination defects during the first month of life.⁵⁴ Ultrastructural studies demonstrate a reduced density of myelinated axons in the WM despite normal axon number.⁵⁴

Of the eight dystonia genes with a role in myelination, six genes (Table 1; *THAP1*, *SLC2A1/GLUT1*, *FA2H*, *YY1*, *SLC16A2/MCT8*, and *TUBB4A*) have an established function within the oligodendrocyte lineage, of which five (Table 1; *THAP1*, *FA2H*, *YY1*, *SLC16A2/MCT8*, and *TUBB4A*) have a regulatory role in the generation of mature OLs. Thus far, mutations for *THAP1*, *FA2H*, *YY1*, and *SLC16A2/MCT8* have been established to result in loss of function.⁹³⁻⁹⁸ Studies using mouse models have demonstrated that both *THAP1* and *YY1* regulate the generation of mature OLs from OPCs.^{54,78} Interestingly, *THAP1* and *YY1* are cobound transcription factors that share a large number of target genes, and *YY1* binding is functionally dependent on *THAP1* binding.^{54,94} The *THAP1* null CNS has normal numbers of OPCs and immature OLs, but a clear defect in the progression to mature myelinating OLs both in vitro and in vivo.⁵⁴ Although the mechanism of actions of these six genes implicated in dystonia may vary, their loss of function would commonly affect myelination resulting from their actions within the OL lineage.

ECM-Mediated Plasticity in Motor Learning and Function

CNS axon–glia interactions are profoundly influenced by the ECM, a complex three-dimensional milieu composed of fibrous proteins (eg, collagen, elastin), glycosaminoglycans (GAGs; a class of long unbranched mucopolysaccharides), and GAG-modified proteins (proteoglycans “GAG-PG”).⁹⁹ The brain ECM is estimated to occupy ~20% of the adult brain¹⁰⁰ acting both as a physical scaffold and a signal-organizing center affecting growth, synaptic activity, and neural plasticity.¹⁰¹⁻¹⁰³ Consequently, the ECM has a broad influence on both the development and the plasticity of the CNS, including motor learning and function.

Brain ECM exists in both diffuse and condensed forms.¹⁰⁴ The best characterized CNS ECM structure is the perineuronal net (PNN). PNNs are lattice-like structures composed of CSPGs (chondroitin sulfate proteoglycans) typically surrounding parvalbumin-positive GABAergic interneurons.¹⁰³ The appearance of the defined PNNs around interneurons in the striatal matrix occurs at the end of a critical developmental period (~3 weeks of age) that correlates with the appearance of an adult-like gait from an immature, predominantly forelimb-dependent “crawl.”¹⁰⁵ Enzymatic

TABLE 1 White matter and extracellular matrix abnormalities associated with dystonia

Gene	Phenotype	Evidence of white matter abnormalities ^a			
		Neuroimaging	Myelination	Functional role in oligodendrocyte lineage	Role in ECM ^a
<i>TOR1A</i>	DYT-TOR1A	18			
<i>THAP1</i>	DYT-THAP1	53	54,55	54,56	56,57
<i>KMT2B</i>	DYT- KMT2B	58,59			
<i>VPS16</i>	DYT-VPS16 and MPS-plus syndrome-like disease (mucopolysaccharidoses)	60	60		61
<i>SGCE</i>	DYT-SGCE				62
<i>SLC2A1/ GLUT1</i>	Paroxysmal dyskinesias dystonia	63,64	65	65	
<i>BAP31</i>	Deafness, dystonia, and cerebral hypomyelination	66	66		
<i>FA2H</i>	Spastic paraplegia; dystonia	67	68-70	69,70	
<i>SLC16A2/ MCT8</i>	Allan-Herndon-Dudley syndrome	71-73	72-77	72-74, 77	
<i>YY1</i>	DYT-YY1 and Gabriele-de Vries syndrome		78	78	
<i>POLR3</i>	POLR3-related leukodystrophy	79,80	79,80		
<i>TUBB4A</i>	DYT-TUBB4A and leukodystrophy including hypomyelination with atrophy of basal ganglia and cerebellum	81,82	81	83,84	

^aReferences to prior studies for inherited dystonia genes and their relation to white matter, oligodendrocytes, and extracellular matrix (ECM). SGCE, e-sarcoglycan.

ablation of these striatal CSPGs impedes the transition to a mature gait,¹⁰⁶ suggesting an important role in motor function during development. PNNs also form around parvalbumin-positive neurons during critical periods of postnatal development in the somatosensory cortex.^{107,108} Sensory deprivation leads to quantitative and qualitative changes in PNNs in the mouse barrel¹⁰⁷ and somatosensory cortex.¹⁰⁹ These observations establish a role for ECM composition and dynamics in establishing sensory and motor function during CNS development.

Despite their necessary role in establishing motor function during development, the effect of CSPGs on motor function is complex and not binary or unidirectional. For instance, injuries in the CNS lead to acute accumulation of CSPGs, which inhibit neural plasticity and oligodendrogenesis.^{101,108,110-116} Motor learning deficits following focal motor cortex ischemia¹¹⁷ or cervical spinal cord injuries¹¹⁸ are ameliorated by enzymatic ablation of the accumulating CSPGs; these observations suggest that lesion-induced ECM accumulation inhibits motor recovery. Multiple GAG species,

in their free forms and as proteoglycans, have been demonstrated to inhibit oligodendrocyte maturation in vitro and in vivo.^{101,110-116,119-122}

Genetic Links Between ECM and Dystonia

Thus far three genetic causes of inherited dystonias have interactions with or contribute to ECM homeostasis (Table 1; *THAP1*, *SGCE*, and *VPS16*). e-sarcoglycan (SGCE) is a transmembrane glycoprotein interacting with extracellular ECM and the intracellular cytoskeleton.⁶¹ Recent studies have identified that *THAP1* is involved in the lysosomal regulation of ECM components.⁵⁶ *THAP1* regulates catabolism of GAGs, the major ECM components in the OL lineage.⁵⁶ Loss of *THAP1* in OPCs results in the accumulation and excess secretion of GAGs, inhibiting OPC maturation through an autoinhibitory mechanism.⁵⁶ *THAP1* regulates GAG catabolism by binding to and regulating the *GusB* (*MPS7*) gene encoding the GAG-catabolizing

enzyme β -glucuronidase,⁵⁶ which resides in the lysosomes and whose loss of function is responsible for the lysosomal storage disorder, mucopolysaccharidosis type VII, or sly syndrome.¹²³ Interestingly, loss-of-function variants in the homotypic fusion and vacuole protein sorting (HOPS) complex genes *VPS16* and *VPS41* have been identified to cause early-onset dystonia.¹²⁴ HOPS is a conserved protein complex known to mediate lysosomal (endosome–lysosome and autophagosome–lysosome) fusion events.¹²⁵ Two recent studies have identified that homozygous *VPS16* variants are associated with a novel disease, resembling mucopolysaccharidosis-plus syndrome and that includes developmental delay, delayed myelination, skeletal abnormalities, and high-normal GAG excretion.^{60,61}

Concluding Remarks

There is increasing evidence for the role of extraneuronal mechanisms in neurodevelopmental and neurodegenerative disorders. In this brief report, we have curated and discussed a growing body of work linking abnormalities of myelination and ECM biology to dystonia pathogenesis and pathophysiology. The roles of other glial populations (eg, astrocytes and microglia) in motor function are relatively well studied but have not been examined in the context of dystonia. This omission is especially pertinent given recent studies demonstrating microglial–astrocyte crosstalk with themselves and with oligodendrocytes. Similarly, astrocytes and microglia have an established role in ECM generation and regulation. Given the wide range of cellular and physiological pathways implicated in dystonia pathogenesis, the roles of these extraneuronal mechanisms and neuronal–glial interactions are important future directions to pursue to unravel the cellular and molecular mechanisms of neurodevelopmental disease, including dystonia. ■

Acknowledgments: This research was supported in part by a National Institutes of Health, National Institute of Neurological Disorders and Stroke grant (1R01NS109227 to W.T.D.). We thank Cathy Collins for critical reading of the manuscript.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References

- Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. *Mov Disord* 2013;28(7):863–873.
- Grutz K, Klein C. Dystonia updates: definition, nomenclature, clinical classification, and etiology. *J Neural Transm (Vienna)* 2021;128(4):395–404.
- Tanabe LM, Kim CE, Alagem N, Dauer WT. Primary dystonia: molecules and mechanisms. *Nat Rev Neurol* 2009;5(11):598–609.
- Pappas SS, Darr K, Holley SM, et al. Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons. *Elife* 2015;4:e08352
- Sciamanna G, Tassone A, Mandolesi G, et al. Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. *J Neurosci* 2012;32(35):11991–12004.
- Sciamanna G, Hollis R, Ball C, et al. Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. *Neurobiol Dis* 2012;47(3):416–427.
- Albin RL, Cross D, Cornblath WT, et al. Diminished striatal [123I]iodobenzovesamical binding in idiopathic cervical dystonia. *Ann Neurol* 2003;53(4):528–532.
- Eskow Jaunarajs KL, Scarduzio M, Ehrlich ME, McMahon LL, Standaert DG. Diverse mechanisms lead to common dysfunction of striatal cholinergic interneurons in distinct genetic mouse models of dystonia. *J Neurosci* 2019;39(36):7195–7205.
- Pappas SS, Li J, LeWitt TM, Kim JK, Monani UR, Dauer WT. A cell autonomous torsinA requirement for cholinergic neuron survival and motor control. *Elife* 2018;7:e36691.
- Mazere J, Dilharreguy B, Catheline G, et al. Striatal and cerebellar vesicular acetylcholine transporter expression is disrupted in human DYT1 dystonia. *Brain* 2021;144(3):909–923.
- Hallett M. Neurophysiology of dystonia: the role of inhibition. *Neurobiol Dis* 2011;42(2):177–184.
- Bruggemann N. Contemporary functional neuroanatomy and pathophysiology of dystonia. *J Neural Transm (Vienna)* 2021;128(4):499–508.
- Nakashima K, Rothwell JC, Day BL, Thompson PD, Shannon K, Marsden CD. Reciprocal inhibition between forearm muscles in patients with writer's cramp and other occupational cramps, symptomatic hemidystonia and hemiparesis due to stroke. *Brain* 1989;112(Pt 3):681–697.
- Tisch S, Limousin P, Rothwell JC, et al. Changes in forearm reciprocal inhibition following pallidal stimulation for dystonia. *Neurology* 2006;66(7):1091–1093.
- Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. *Mov Disord* 2013;28(7):958–967.
- Carbon M, Argyelan M, Ghilardi MF, et al. Impaired sequence learning in dystonia mutation carriers: a genotypic effect. *Brain* 2011;134(Pt 5):1416–1427.
- Ulug AM, Vo A, Argyelan M, et al. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. *Proc Natl Acad Sci U S A* 2011;108(16):6638–6643.
- Carbon M, Kingsley PB, Su S, et al. Microstructural white matter changes in carriers of the DYT1 gene mutation. *Ann Neurol* 2004;56(2):283–286.
- Poston KL, Eidelberg D. Functional brain networks and abnormal connectivity in the movement disorders. *Neuroimage* 2012;62(4):2261–2270.
- Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. *J Neurosci* 2009;29(31):9740–9747.
- DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. *Arch Neurol* 2007;64(1):20–24.
- Ismail FY, Fatemi A, Johnston MV. Cerebral plasticity: windows of opportunity in the developing brain. *Eur J Paediatr Neurol* 2017;21(1):23–48.
- Quartarone A, Pisani A. Abnormal plasticity in dystonia: disruption of synaptic homeostasis. *Neurobiol Dis* 2011;42(2):162–170.
- Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? *Trends Neurosci* 2006;29(4):192–199.
- Li J, Kim S, Pappas SS, Dauer WT. CNS critical periods: implications for dystonia and other neurodevelopmental disorders. *JCI Insight* 2021;6(4):e142483

26. Li J, Levin DS, Kim AJ, Pappas SS, Dauer WT. TorsinA restoration in a mouse model identifies a critical therapeutic window for DYT1 dystonia. *J Clin Invest* 2021;131(6):e139606
27. Tanabe LM, Liang CC, Dauer WT. Neuronal nuclear membrane budding occurs during a developmental window modulated by Torsin Paralogs. *Cell Rep* 2016;16(12):3322–3333.
28. Zech M, Boesch S, Skorvanek M, et al. Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. *Parkinsonism Relat Disord* 2021;84:129–134.
29. Wirth T, Tranchant C, Drouot N, et al. Increased diagnostic yield in complex dystonia through exome sequencing. *Parkinsonism Relat Disord* 2020;74:50–56.
30. Zech M, Jech R, Boesch S, et al. Monogenic variants in dystonia: an exome-wide sequencing study. *Lancet Neurol* 2020;19(11):908–918.
31. Keller Sarmiento IJ, Mencacci NE. Genetic Dystonias: update on classification and new genetic discoveries. *Curr Neurol Neurosci Rep* 2021;21(3):8
32. Dauer WT. Neurogenetic disease: genes, mechanisms, and future promise. *Neurotherapeutics* 2014;11(4):697–698.
33. Ding J, Adiconis X, Simmons SK, et al. Systematic comparative analysis of single cell RNA-sequencing methods. *bioRxiv* 2019; 632216. <https://www.biorxiv.org/content/10.1101/632216v2.full>
34. Waxman SG, Bennett MV. Relative conduction velocities of small myelinated and non-myelinated fibres in the central nervous system. *Nat New Biol* 1972;238(85):217–219.
35. Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ. Brain development in rodents and humans: identifying benchmarks of maturation and vulnerability to injury across species. *Prog Neurobiol* 2013;106–107:1–16.
36. Keshavan MS, Diwadkar VA, DeBellis M, et al. Development of the corpus callosum in childhood, adolescence and early adulthood. *Life Sci* 2002;70(16):1909–1922.
37. Rice D, Barone S Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. *Environ Health Perspect* 2000;108(suppl 3):511–533.
38. van Tilborg E, de Theije CGM, van Hal M, et al. Origin and dynamics of oligodendrocytes in the developing brain: implications for perinatal white matter injury. *Glia* 2018;66(2):221–238.
39. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. *Arch Gen Psychiatry* 2001;58(5):461–465.
40. McKenzie IA, Ohayon D, Li H, et al. Motor skill learning requires active central myelination. *Science* 2014;346(6207):318–322.
41. Xiao L, Ohayon D, McKenzie IA, et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. *Nat Neurosci* 2016;19(9):1210–1217.
42. Bacmeister CM, Barr HJ, McClain CR, et al. Motor learning promotes remyelination via new and surviving oligodendrocytes. *Nat Neurosci* 2020;23(7):819–831.
43. Stevens B, Tanner S, Fields RD. Control of myelination by specific patterns of neural impulses. *J Neurosci* 1998;18(22):9303–9311.
44. Wake H, Lee PR, Fields RD. Control of local protein synthesis and initial events in myelination by action potentials. *Science* 2011; 333(6049):1647–1651.
45. Gibson EM, Purger D, Mount CW, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. *Science* 2014;344(6183):1252304
46. Mancini M, Karakuzu A, Cohen-Adad J, Cercignani M, Nichols TE, Stikov N. An interactive meta-analysis of MRI biomarkers of myelin. *Elife* 2020;9:e61523.
47. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. *Neurotherapeutics* 2007;4(3):316–329.
48. Chang EH, Argyelan M, Aggarwal M, et al. The role of myelination in measures of white matter integrity: combination of diffusion tensor imaging and two-photon microscopy of CLARITY intact brains. *Neuroimage* 2017;147:253–261.
49. Bengtsson SL, Nagy Z, Skare S, Forsman L, Forssberg H, Ullen F. Extensive piano practicing has regionally specific effects on white matter development. *Nat Neurosci* 2005;8(9):1148–1150.
50. Scholz J, Klein MC, Behrens TE, Johansen-Berg H. Training induces changes in white-matter architecture. *Nat Neurosci* 2009; 12(11):1370–1371.
51. Piervincenzi C, Ben-Soussan TD, Mauro F, et al. White matter microstructural changes following Quadrato motor training: A longitudinal study. *Front Hum Neurosci* 2017;11:590
52. Sampaio-Baptista C, Khrapitchev AA, Foxley S, et al. Motor skill learning induces changes in white matter microstructure and myelination. *J Neurosci* 2013;33(50):19499–19503.
53. Cheng FB, Wan XH, Feng JC, et al. Subcellular distribution of THAP1 and alterations in the microstructure of brain white matter in DYT6 dystonia. *Parkinsonism Relat Disord* 2012;18(8): 978–982.
54. Yellajoshiyula D, Liang CC, Pappas SS, et al. The DYT6 dystonia protein THAP1 regulates myelination within the Oligodendrocyte lineage. *Dev Cell* 2017;42(1):52–67 e54.
55. Domingo A, Yadav R, Shah S, et al. Dystonia-specific mutations in THAP1 alter transcription of genes associated with neurodevelopment and myelin. *Am J Human Genet* 2021;108(11):2145–2158.
56. Yellajoshiyula D, Pappas SS, Rogers AE, et al. THAP1 modulates oligodendrocyte maturation by regulating ECM degradation in lysosomes. *Proc Natl Acad Sci* 2021;118(31):e2100862118.
57. Baumann H, Ott F, Weber J, et al. Linking penetrance and transcription in DYT-THAP1: insights from a human iPSC-derived cortical model. *Mov Disord* 2021;36(6):1381–1391.
58. Baizabal-Carvalho JF, Alonso-Juarez M. Generalized dystonia associated with mutation in the histone methyltransferase gene KMT2B (DYT28) and white matter abnormalities. *Parkinsonism Relat Disord* 2018;49:116–117.
59. Gif L, Demailly D, Lin JP, et al. KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. *Brain* 2020;143(11):3242–3261.
60. Sofou K, Meier K, Sanderson LE, et al. Bi-allelic VPS16 variants limit HOPS/CORVET levels and cause a mucopolysaccharidosis-like disease. *EMBO Mol Med* 2021;13(5):e13376
61. Yildiz Y, Kosukcu C, Aygun D, et al. Homozygous missense VPS16 variant is associated with a novel disease, resembling mucopolysaccharidosis-plus syndrome in two siblings. *Clin Genet* 2021;100(3):308–317.
62. Waite A, Brown SC, Blake DJ. The dystrophin-glycoprotein complex in brain development and disease. *Trends Neurosci* 2012; 35(8):487–496.
63. Auvin S. Abnormal white matter: expanding the GLUT1-D phenotype. *Eur J Paediatr Neurol* 2018;22(3):345
64. Ismayilova N, Hacoheh Y, MacKinnon AD, Elmslie F, Clarke A. GLUT-1 deficiency presenting with seizures and reversible leukoencephalopathy on MRI imaging. *Eur J Paediatr Neurol* 2018; 22(6):1161–1164.
65. Saab AS, Tzvetavona ID, Trevisiol A, et al. Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism. *Neuron* 2016;91(1):119–132.
66. Cacciagli P, Sutera-Sardo J, Borges-Correia A, et al. Mutations in BCAP31 cause a severe X-linked phenotype with deafness, dystonia, and central hypomyelination and disorganize the Golgi apparatus. *Am J Hum Genet* 2013;93(3):579–586.
67. Mari F, Berti B, Romano A, et al. Clinical and neuroimaging features of autosomal recessive spastic paraplegia 35 (SPG35): case reports, new mutations, and brief literature review. *Neurogenetics* 2018;19(2):123–130.
68. Eckhardt M, Yaghoofam A, Fewou SN, Zoller I, Gieselmann V. A mammalian fatty acid hydroxylase responsible for the formation of alpha-hydroxylated galactosylceramide in myelin. *Biochem J* 2005; 388(Pt 1):245–254.
69. Hardt R, Jordans S, Winter D, Gieselmann V, Wang-Eckhardt L, Eckhardt M. Decreased turnover of the CNS myelin protein Opalin

- in a mouse model of hereditary spastic paraplegia 35. *Hum Mol Genet* 2021;29(22):3616–3630.
70. Zoller I, Meixner M, Hartmann D, et al. Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. *J Neurosci* 2008;28(39):9741–9754.
 71. Gika AD, Siddiqui A, Hulse AJ, et al. White matter abnormalities and dystonic motor disorder associated with mutations in the SLC16A2 gene. *Dev Med Child Neurol* 2010;52(5):475–482.
 72. Charzewska A, Wierzba J, Izycka-Swieszewska E, et al. Hypomyelinating leukodystrophies - a molecular insight into the white matter pathology. *Clin Genet* 2016;90(4):293–304.
 73. Vancamp P, Demeneix BA, Rемаud S. Monocarboxylate transporter 8 deficiency: delayed or permanent Hypomyelination? *Front Endocrinol (Lausanne)* 2020;11:283
 74. López-Espindola D, Morales-Bastos C, Grijota-Martínez C, et al. Mutations of the thyroid hormone transporter MCT8 cause prenatal brain damage and persistent hypomyelination. *J Clin Endocrinol Metab* 2014;99(12):E2799–E2804.
 75. La Piana R, Vanasse M, Brais B, Bernard G. Myelination delay and Allan-Herndon-Dudley syndrome caused by a novel mutation in the SLC16A2 gene. *J Child Neurol* 2015;30(10):1371–1374.
 76. Shimojima K, Maruyama K, Kikuchi M, Imai A, Inoue K, Yamamoto T. Novel SLC16A2 mutations in patients with Allan-Herndon-Dudley syndrome. *Intract Rare Dis Res* 2016;5(3): 214–217.
 77. Lee JY, Kim MJ, Deliyanti D, et al. Overcoming Monocarboxylate transporter 8 (MCT8)-deficiency to promote human Oligodendrocyte differentiation and myelination. *EBioMedicine* 2017;25: 122–135.
 78. He Y, Dupree J, Wang J, et al. The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. *Neuron* 2007;55(2):217–230.
 79. Al Yazidi G, Tran LT, Guerrero K, et al. Dystonia in RNA polymerase III-related Leukodystrophy. *Mov Disord Clin Pract* 2019; 6(2):155–159.
 80. Hiraide T, Kubota K, Kono Y, et al. POLR3A variants in striatal involvement without diffuse hypomyelination. *Brain Dev* 2020; 42(4):363–368.
 81. Tonduti D, Aiello C, Renaldo F, et al. TUBB4A-related hypomyelinating leukodystrophy: new insights from a series of 12 patients. *Eur J Paediatr Neurol* 2016;20(2):323–330.
 82. Bally JF, Camargos S, Oliveira Dos Santos C, et al. DYT-TUBB4A (DYT4 dystonia): new clinical and genetic observations. *Neurology* 2021;96(14):e1887–e1897.
 83. Curiel J, Rodriguez Bey G, Takanohashi A, et al. TUBB4A mutations result in specific neuronal and oligodendrocytic defects that closely match clinically distinct phenotypes. *Hum Mol Genet* 2017; 26(22):4506–4518.
 84. Sase S, Almad AA, Boecker CA, et al. TUBB4A mutations result in both glial and neuronal degeneration in an H-ABC leukodystrophy mouse model. *Elife* 2020;9:e52986.
 85. Lehericy S, Tijssen MA, Vidailhet M, Kaji R, Meunier S. The anatomical basis of dystonia: current view using neuroimaging. *Mov Disord* 2013;28(7):944–957.
 86. Fabbrini G, Pantano P, Totaro P, et al. Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm. *Eur J Neurol* 2008;15(2):185–189.
 87. Blood AJ, Kuster JK, Waugh JL, et al. White matter changes in cervical dystonia relate to clinical effectiveness of Botulinum toxin treatment. *Front Neurol* 2019;10:265
 88. Blood AJ, Tuch DS, Makris N, Makhlof ML, Sudarsky LR, Sharma N. White matter abnormalities in dystonia normalize after botulinum toxin treatment. *Neuroreport* 2006;17(12):1251–1255.
 89. Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. *Nat Genet* 2009;41(3):286–288.
 90. Roussigne M, Cayrol C, Clouaire T, Amalric F, Girard JP. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies. *Oncogene* 2003;22(16): 2432–2442.
 91. Clouaire T, Roussigne M, Ecochard V, Mathe C, Amalric F, Girard JP. The THAP domain of THAP1 is a large C2CH module with zinc-dependent sequence-specific DNA-binding activity. *Proc Natl Acad Sci U S A* 2005;102(19):6907–6912.
 92. Domingo A, Yadav R, Ozelius LJ. Isolated dystonia: clinical and genetic updates. *J Neural Transm* 2021;128(4):405–416. <https://doi.org/10.1007/s00702-020-02268-x>
 93. Maranduba CM, Friesema EC, Kok F, et al. Decreased cellular uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporter. *J Med Genet* 2006;43(5):457–460.
 94. Yellajoshuyula D, Rogers AE, Kim AJ, Kim S, Pappas SS, Dauer WT. A pathogenic DYT-THAP1 dystonia mutation causes hypomyelination and loss of YY1 binding. *Hum Mol Genet* 2021. <https://doi.org/10.1093/hmg/ddab310>
 95. Jansen J, Friesema EC, Kester MH, et al. Functional analysis of monocarboxylate transporter 8 mutations identified in patients with X-linked psychomotor retardation and elevated serum triiodothyronine. *J Clin Endocrinol Metab* 2007;92(6):2378–2381.
 96. Rattay TW, Lindig T, Baets J, et al. FAHN/SPG35: a narrow phenotypic spectrum across disease classifications. *Brain* 2019;142(6): 1561–1572.
 97. Malaquias MJ, Damasio J, Mendes A, Freixo JP, Magalhaes M. A case of YY1-related isolated dystonia with severe Oromandibular involvement. *Mov Disord* 2021;36(11):2705–2706.
 98. Ferng A, Thulin P, Walsh E, Weissbrod PA, Friedman J. Yy1: a new gene for childhood onset dystonia with prominent oromandibular-laryngeal involvement?. *Mov Disord* 2022;37(3): 227–228.
 99. Lindahl U, Couchman J, Kimata K, Esko JD. Proteoglycans and sulfated Glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, et al., eds. *Essentials of Glycobiology*. New York: Cold Spring Harbor; 2015:207–221.
 100. Sykova E, Nicholson C. Diffusion in brain extracellular space. *Physiol Rev* 2008;88(4):1277–1340.
 101. Cognato H, Tzvetanova ID. Glia unglued: how signals from the extracellular matrix regulate the development of myelinating glia. *Dev Neurobiol* 2011;71(11):924–955.
 102. Theocharidis U, Long K, Ffrench-Constant C, Faissner A. Regulation of the neural stem cell compartment by extracellular matrix constituents. *Prog Brain Res* 2014;214:3–28.
 103. Fawcett JW, Oohashi T, Pizzorusso T. The roles of perineuronal nets and the perinodal extracellular matrix in neuronal function. *Nat Rev Neurosci* 2019;20(8):451–465.
 104. Miyata S, Kitagawa H. Formation and remodeling of the brain extracellular matrix in neural plasticity: roles of chondroitin sulfate and hyaluronan. *Biochim Biophys Acta Gen Subj* 2017;1861(10): 2420–2434.
 105. Lee H, Leamey CA, Sawatari A. Rapid reversal of chondroitin sulfate proteoglycan associated staining in subcompartments of mouse neostriatum during the emergence of behaviour. *PLoS One* 2008; 3(8):e3020
 106. Lee H, Leamey CA, Sawatari A. Perineuronal nets play a role in regulating striatal function in the mouse. *PLoS One* 2012;7(3): e32747
 107. McRae PA, Rocco MM, Kelly G, Brumberg JC, Matthews RT. Sensory deprivation alters aggrecan and perineuronal net expression in the mouse barrel cortex. *J Neurosci* 2007;27(20):5405–5413.
 108. Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. *Science* 2002;298(5596):1248–1251.
 109. Ueno H, Suemitsu S, Okamoto M, Matsumoto Y, Ishihara T. Sensory experience-dependent formation of perineuronal nets and expression of Cat-315 immunoreactive components in the mouse somatosensory cortex. *Neuroscience* 2017;355:161–174.
 110. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and

- remyelination through TLR2. *Proc Natl Acad Sci U S A* 2010; 107(25):11555–11560.
111. Siebert JR, Osterhout DJ. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. *J Neurochem* 2011;119(1): 176–188.
 112. Lau LW, Keough MB, Haylock-Jacobs S, et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. *Ann Neurol* 2012;72(3):419–432.
 113. Karus M, Ulc A, Ehrlich M, et al. Regulation of oligodendrocyte precursor maintenance by chondroitin sulphate glycosaminoglycans. *Glia* 2016;64(2):270–286.
 114. Keough MB, Rogers JA, Zhang P, et al. An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. *Nat Commun* 2016;7:11312
 115. Kuboyama K, Tanga N, Suzuki R, Fujikawa A, Noda M. Protamine neutralizes chondroitin sulfate proteoglycan-mediated inhibition of oligodendrocyte differentiation. *PLoS One* 2017;12(12): e0189164
 116. Pu A, Stephenson EL, Yong VW. The extracellular matrix: Focus on oligodendrocyte biology and targeting CSPGs for remyelination therapies. *Glia* 2018;66(9):1809–1825. <https://doi.org/10.1002/glia.23333>
 117. Gherardini L, Gennaro M, Pizzorusso T. Perilesional treatment with chondroitinase ABC and motor training promote functional recovery after stroke in rats. *Cereb Cortex* 2015;25(1):202–212.
 118. Garcia-Alias G, Lin R, Akrimi SF, Story D, Bradbury EJ, Fawcett JW. Therapeutic time window for the application of chondroitinase ABC after spinal cord injury. *Exp Neurol* 2008; 210(2):331–338.
 119. Harlow DE, Macklin WB. Inhibitors of myelination: ECM changes. CSPGs and PTPs *Exp Neurol* 2014;251:39–46.
 120. Dyck S, Kataria H, Akbari-Kelachayeh K, Silver J, Karimi-Abdolrezaee S. LAR and PTPsigma receptors are negative regulators of oligodendrogenesis and oligodendrocyte integrity in spinal cord injury. *Glia* 2019;67(1):125–145.
 121. Luo F, Tran AP, Xin L, et al. Modulation of proteoglycan receptor PTPsigma enhances MMP-2 activity to promote recovery from multiple sclerosis. *Nat Commun* 2018;9(1):4126
 122. Djerbal L, Lortat-Jacob H, Kwok J. Chondroitin sulfates and their binding molecules in the central nervous system. *Glycoconj J* 2017; 34(3):363–376.
 123. Sly WS, Brot FE, Glaser J, et al. Beta-glucuronidase deficiency mucopolysaccharidosis. *Birth Defects Orig Artic Ser* 1974;10(12): 239–245.
 124. Steel D, Zech M, Zhao C, et al. Loss-of-function variants in HOPS complex genes VPS16 and VPS41 cause early onset dystonia associated with Lysosomal abnormalities. *Ann Neurol* 2020;88(5): 867–877.
 125. Balderhaar HJ, Ungermann C. CORVET and HOPS tethering complexes - coordinators of endosome and lysosome fusion. *J Cell Sci* 2013;126(Pt 6):1307–1316.